TITLE:
Feasibility Study on Listing of Pharmaceutical Enterprises Based on Financial Analysis: Take Company Y as an Example
AUTHORS:
Yan Ma
KEYWORDS:
Chinese Medicine Industry, Y Company, Listing Valuation, Financial Analysis
JOURNAL NAME:
Open Journal of Business and Management,
Vol.9 No.3,
May
31,
2021
ABSTRACT: Health has always been one of people’s demands for a high quality of
life. For thousands of years, both Chinese and Western medicine have
accumulated a lot of medical knowledge and ideas. However, due to the weakness
of China in the past century, Chinese medicine has become irrelevant. However, with the outbreak and persistence of COVID-19 and China’s
actions in the fight against the epidemic, people have further realized the
importance of health, and TCM has again entered people’s field of vision.
Taking Company Y as an example, this paper analyzes the listing feasibility of
Company Y from its macro environment, basic overview, advantages and
disadvantages in the industry, financial indicators, enterprise valuation and
other aspects. Then, based on the above analysis and combined with the
development trend and recent development goals of the enterprise, it concludes
that under the current macro and micro environment, Company Y can and should be
encouraged to list on the New Third Board, with a stock price of about 7 yuan
and a price-earnings ratio of about 25 times.